RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Rating of "Hold" by Brokerages

RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has been assigned an average recommendation of "Hold" from the nine analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $4.00.

Separately, HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of RAPT Therapeutics in a report on Monday, March 10th.

RAPT Therapeutics Price Performance

Shares of RAPT stock traded down $0.01 during trading hours on Monday, hitting $0.79. The company had a trading volume of 781,946 shares, compared to its average volume of 1,273,344. The stock has a market capitalization of $104.35 million, a PE ratio of -0.29 and a beta of -0.29. The company's fifty day moving average is $1.12 and its 200 day moving average is $1.36. RAPT Therapeutics has a fifty-two week low of $0.75 and a fifty-two week high of $8.58.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last released its quarterly earnings results on Thursday, March 6th. The company reported ($1.14) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.69). Equities analysts forecast that RAPT Therapeutics will post -2.14 earnings per share for the current year.

Institutional Investors Weigh In On RAPT Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. Picton Mahoney Asset Management increased its stake in shares of RAPT Therapeutics by 994.4% during the fourth quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company's stock worth $26,000 after buying an additional 14,697 shares during the period. JPMorgan Chase & Co. grew its holdings in RAPT Therapeutics by 298.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company's stock worth $34,000 after acquiring an additional 25,130 shares in the last quarter. Simplicity Wealth LLC purchased a new stake in shares of RAPT Therapeutics in the 1st quarter valued at approximately $25,000. Barclays PLC raised its holdings in shares of RAPT Therapeutics by 277.2% in the 3rd quarter. Barclays PLC now owns 39,729 shares of the company's stock valued at $79,000 after purchasing an additional 29,195 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of RAPT Therapeutics during the 4th quarter worth $63,000. Institutional investors and hedge funds own 99.09% of the company's stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.